Cargando…

Efficacy of tocilizumab treatment in severely ill COVID-19 patients

Detalles Bibliográficos
Autores principales:	Zhao, Jie, Cui, Wei, Tian, Bao-ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450680/ https://www.ncbi.nlm.nih.gov/pubmed/32854738 http://dx.doi.org/10.1186/s13054-020-03224-7

Ejemplares similares

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients
por: Zeng, Jia, et al.
Publicado: (2020)

Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia
por: Gokhale, Yojana, et al.
Publicado: (2020)

Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients
por: Bhandari, Sudhir, et al.
Publicado: (2021)

Effective treatment of severe COVID-19 patients with tocilizumab
por: Xu, Xiaoling, et al.
Publicado: (2020)

Tocilizumab is recommended for the treatment of severe COVID-19
por: Zhou, Yonggang, et al.
Publicado: (2020)

Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19
por: Abbasian, Ladan, et al.
Publicado: (2022)

Authors’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Liu, Bin, et al.
Publicado: (2020)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients
por: Wang, Yong, et al.
Publicado: (2022)

High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
por: Mandal, M., et al.
Publicado: (2022)

Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes
por: Al-Baadani, Abeer, et al.
Publicado: (2021)

Efficacy and safety of tocilizumab in COVID-19 patients
por: Zheng, Kai-Lian, et al.
Publicado: (2020)

Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients
por: Piconi, Stefania, et al.
Publicado: (2023)

Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis
por: Luo, Lili, et al.
Publicado: (2022)

Why tocilizumab could be an effective treatment for severe COVID-19?
por: Fu, Binqing, et al.
Publicado: (2020)

Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience
por: Jiménez-Brítez, Gustavo, et al.
Publicado: (2020)

Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience
por: Jiménez-Brítez, Gustavo, et al.
Publicado: (2020)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021)

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
por: Stone, John H., et al.
Publicado: (2020)

Tocilizumab in critically ill COVID-19 patients: An observational study
por: Mushtaq, Muhammad Z., et al.
Publicado: (2022)

Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia
por: Shinomiya, Shohei, et al.
Publicado: (2021)

Could Tocilizumab be an Attractive Therapeutic Option for Elderly Patients with Severe COVID-19? A Case Report
por: Streicher, Caroline, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19
por: Widysanto, Allen, et al.
Publicado: (2021)

Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study
por: Huang, Edmund, et al.
Publicado: (2021)

IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
por: Dufranc, Etienne, et al.
Publicado: (2020)

Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness
por: Rubio-Rivas, Manuel, et al.
Publicado: (2020)

Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia
por: Agirbasli, Mehmet, et al.
Publicado: (2021)

Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply
por: Kashour, Tarek, et al.
Publicado: (2021)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Predictors of the Outcomes Following the Tocilizumab Treatment for Severe COVID-19
por: Singla, Karan, et al.
Publicado: (2022)

Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics
por: Elhazmi, Alyaa, et al.
Publicado: (2023)

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
por: Foo, Hong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a0glst227usabbuiudl8t7dic0